Friday - April 4, 2025
Gubra Enters $2.225 Billion License Agreement with AbbVie to Develop an Amylin Analog for the Treatment of Obesity
March 13, 2025
BOSTON, Massachusetts, March 13 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release:

* * *

Gubra Enters $2.225 Billion License Agreement with AbbVie to Develop an Amylin Analog for the Treatment of Obesity

A multijurisdictional Life Sciences team advised Gubra A/S ("Gubra") on its licensing agreement with AbbVie Inc. to develop a potential best-in-class, long-acting amylin analog for the treatment of obesity. Under t . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products